Login / Signup

Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib.

Ajay DhakalRoby Antony ThomasEllis G LevineAdam BrufskyKazuaki TakabeMatthew G HannaKristopher AttwoodAustin MillerThaer KhouryAmy P EarlySaif SoniwalaTracy O'ConnorMateusz Opyrchal
Published in: Breast cancer : basic and clinical research (2020)
Everolimus was associated with modest PFS and ORR in HR+ HER2-MBCs postprogression on palbociclib.
Keyphrases
  • metastatic breast cancer
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • peritoneal dialysis
  • prognostic factors
  • stem cells
  • patient reported outcomes
  • mesenchymal stem cells